Rucaparib is an investigational drug that kills cancer cells by blocking the PARP protein, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more vulnerable to anticancer treatments. In this study, researchers want to see if giving rucaparib to women with ovarian, fallopian tube, or primary peritoneal cancer whose tumors shrank with platinum-based chemotherapy can reduce the chance that the cancer will spread or come back.
Patient will be randomly assigned to receive rucaparib (two-thirds of the patients) or a placebo (the other one-third). The rucaparib in this study is being given as a tablet that can be taken orally (by mouth).
Doctors also want to see if certain biomarkers, such as a patient’s BRCA mutation status, affect response to treatment.